Obsidian Therapeutics, a biotechnology company, unveiled promising updates on its Phase 1 study of OBX-115, a tumor-infiltrating lymphocyte (TIL) cell therapy, at the American Association for Cancer Research (AACR) Annual Meeting.
OBX-115 is being tested in patients with advanced melanoma who have not responded to immune checkpoint inhibitors (ICIs). Six patients received OBX-115 in the study, and the safety data collected over 25 weeks showed it was well-tolerated.
Crucially, OBX-115 demonstrated sustained and effective responses in reducing tumor growth. Rodabe N. Amaria, the study’s principal investigator, highlighted that OBX-115 is unique in not requiring interleukin 2 (IL2), a cytokine often used with TIL cell therapies but can cause severe side effects.
Parameswaran Hari, Obsidian’s Chief Development Officer, expressed optimism about OBX-115’s potential to expand the eligibility for TIL cell therapy and address the unmet need in ICI-resistant advanced melanoma. Obsidian is also conducting a multicenter Phase 1/2 study involving metastatic melanoma and non-small cell lung cancer patients.
Additionally, Obsidian presented three other posters at AACR 2024, detailing research on TILs engineered with membrane-bound IL15 and LIGHT (TNFSF14). These studies demonstrate Obsidian’s continued commitment to advancing engineered cell and gene therapies for treating cancer.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.